DelveInsight’s, “Malaria Pipeline Insights 2026” Report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Malaria pipeline landscape. It covers the Malaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Malaria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Malaria Pipeline @ Malaria Pipeline Outlook
Key Takeaways from the Malaria Pipeline Report
- In March 2026- Novartis Pharmaceuticals conducted a study (NCT05750628) was the open-label, randomized, two-arm combination therapy evaluating a single oral dose of up to three anti-malarial agents as a loose combination vs. standard of care (SoC), Coartem in adult and adolescent participants.
- In February 2026- Merck Healthcare KGaA initiated a phase 2 study evaluates the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and adolescents. The study will also assess the duration of protection provided by different doses of M5717 plus pyronaridine and the additional contribution of M5717 to the duration of protection using external study data.
- DelveInsight’s Malaria pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Malaria treatment.
- The leading Malaria Companies such as Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Sumitomo Pharma, Zymergen and others.
- Promising Malaria Pipeline Therapies such as KAE609, Coartem, VMP001, BNT165e, Meplazumab for Injection, KAF156, INE963, KLU156 and others.
Stay ahead with the most recent pipeline outlook for Malaria @ Malaria Treatment Drugs
The Malaria Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Malaria Pipeline Report also highlights the unmet needs with respect to the Malaria.
Malaria Overview
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. In 2019, there were an estimated 229 million cases of malaria worldwide. Malaria is caused by Plasmodium parasites. The parasites are spread to people through the bites of infected female Anopheles mosquitoes, called “malaria vectors.” There are 5 parasite species that cause malaria in humans, and 2 of these species – P. falciparum and P. vivax – pose the greatest threat. Malaria is an acute febrile illness. In a non-immune individual, symptoms usually appear 10–15 days after the infective mosquito bite. The first symptoms – fever, headache, and chills – may be mild and difficult to recognize as malaria. If not treated within 24 hours, P. falciparum malaria can progress to severe illness, often leading to death.
Malaria Emerging Drugs Profile
- Cipargamin: Novartis
Cipargamin is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over 20 years. Cipargamin, the first compound in the spiroindolone class of treatment, works through a novel mechanism of action that involves inhibition of a P-type cation-transporter ATPase4 (PfATP4), which regulates sodium concentration in the parasite. Because Cipargamin could potentially help prevent disease transmission. Cipargamin was tested in adult patients with uncomplicated malaria and showed a median parasite clearance time of 12 hours, including in patients with resistant infections. Currently the product is in Phase II stage of development for the treatment of Malaria.
The Malaria Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Malaria with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malaria Treatment.
- Malaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Malaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malaria market
Explore groundbreaking therapies and clinical trials in the Malaria Pipeline @ New Malaria Drugs
Malaria Companies
Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Sumitomo Pharma, Zymergen and others.
Malaria Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intranasal
- Intrathecal
- Intravenous
- Oral
- Oral/Intravenous
- Parenteral
- Subcutaneous
- Subcutaneous/Intramuscular
- Transdermal
Malaria Products have been categorized under various Molecule types such as
- Antisense oligonucleotide
- Gene therapy
- Hormones
- Neuropeptides
- Oligonucleotides
- Small Molecule
- Triglyceride
Learn about new drugs, pipeline developments with DelveInsight’s expert analysis @ Malaria Market Drivers and Barriers
Scope of the Malaria Pipeline Report
- Coverage- Global
- Malaria Companies- Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Sumitomo Pharma, Zymergen and others.
- Malaria Pipeline Therapies- KAE609, Coartem, VMP001, BNT165e, Meplazumab for Injection, KAF156, INE963, KLU156 and others.
- Malaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Malaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Malaria Therapies and clinical trials @ Malaria Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Malaria: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Malaria– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- PfSPZ Vaccine: Sanaria
- Drug name : Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Cipargamin: Novartis
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- INE963: Novartis
- Drug name : Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Malaria Key Companies
- Malaria Key Products
- Malaria- Unmet Needs
- Malaria- Market Drivers and Barriers
- Malaria- Future Perspectives and Conclusion
- Malaria Analyst Views
- Malaria Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/malaria-pipeline-insight